MedTrace Logo

A Study to Assess Insulin Delivery With PaQ® in Patients With Type 2 Diabetes Mellitus

NCT02419859 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2016-07-26

No results posted yet for this study

Summary

The purpose of the study is to obtain an assessment (efficacy, safety, and patient reported outcomes) of basal bolus insulin delivery with PaQ in insulin-using patients with type 2 diabetes mellitus (T2DM).

Conditions

Interventions

DEVICE

PaQ® Insulin Delivery Device

PaQ is a 3 day insulin delivery device which delivers U 100 rapid-acting insulin. Provides basal insulin at preset basal doses and bolus insulin (in 2 unit increments) with a push of a button.

DRUG

Insulin, Asp(B28)-

a fast-acting analog of human insulin

Sponsors & Collaborators

  • CeQur Corporation

    lead INDUSTRY

Principal Investigators

  • Thomas Pieber, MD · Medical University of Graz

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-02-28
Primary Completion
2015-11-30
Completion
2015-11-30

Countries

  • Austria

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02419859 on ClinicalTrials.gov